Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Ragothaman Srinivasan

Eliem Concludes Patient Enrolment In Mid-Stage Study Of Radicular Back Pain Drug

Eliem Therapeutics (NASDAQ:ELYM) has completed dosing of the last patient in its Phase 2a trial of ETX-810 in patients with chronic lumbosacral radicular pain (LSRP).

During the Phase 2a proof-of-concept trial evaluating ETX-810 inchronic lumbosacral radicular pain (LSRP), 149 patients are enrolled at sites across the United States.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.